Zhiyu Tang

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine S. Tam, Judith Trotman, Stephen Opat et al. · Blood · 2019 · 367 citations · Full text

Medicine, Oncology, Pharmacology +10

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Yunhang Guo, Ye Liu, Nan Hu et al. · Journal of Medicinal Chemistry · 2019 · 349 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

Tong Zhang, Xiaomin Song, Lanlan Xu et al. · Cancer Immunology Immunotherapy · 2018 · 289 citations · Full text

Pharmacy, Immunology, Oncology +17

Hyperspectral imaging combined with machine learning as a tool to obtain high‐throughput plant salt‐stress phenotyping

Xuping Feng, Yihua Zhan, Qi Wang et al. · The Plant Journal · 2019 · 142 citations · Full text

Agriculture, Agronomy, Plant Sciences +17

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Jayesh Desai, Hui Gan, Catherine Barrow et al. · Journal of Clinical Oncology · 2020 · 109 citations · Full text

Medicine, Oncology, Pharmacology +13